ITIF Logo
ITIF Search
Center for Life Sciences Innovation

Center for Life Sciences Innovation

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play. The Center’s mission is to study and advance the many technology, economic, and policy factors underpinning successful life sciences innovation—from how new technologies like artificial intelligence, genomics, and gene editing are powering the next generation of biomedical innovation to the economics of life sciences innovation, including the role of IP and incentives therein; international competitiveness in life sciences innovation; and foremost the optimal set of public policies, at home and abroad, to spur greater levels of much-needed biopharmaceutical innovation. Read more about the Center, and stay up to date by signing up for ITIF’s weekly email and checking the box to get information about life sciences.

Featured Publications

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Expenditures for retail prescriptions have been roughly stable for the past two decades as a share of total U.S. health-care expenditures. Instead of applying broad price controls, policymakers should promote affordability and mitigate out-of-pocket costs for individuals.

Going, Going, Gone? To Stay Competitive in Biopharmaceuticals, America Must Learn From Its Semiconductor Mistakes

Going, Going, Gone? To Stay Competitive in Biopharmaceuticals, America Must Learn From Its Semiconductor Mistakes

America has lost 70 percent of its semiconductor manufacturing capacity over the last three decades. That serves as a harsh lesson for policymakers: Failing to maintain a supportive policy environment could set up other high-tech industries to falter, too.

Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry

Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry

In her sensationally titled report, “Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients,” the deputy chair of the Congressional Progressive Caucus issued an ideologically inspired jeremiad grounded in assertions that are easily refuted with data.

The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation

The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation

China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.

More Publications

Events

March 29, 2022

How Using March-in Rights Would Threaten America’s Research Universities

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

April 29, 2021

How Intellectual Property Has Played a Pivotal Role in the Global COVID-19 Response

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

April 21, 2021

Seizing the Transformative Opportunity of Multi-cancer Early Detection

ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

March 25, 2021

March-In Rights for Federally Funded Inventions: A Primer

ITIF and the Bayh-Dole Coalition hosted a joint video webinar that will clarify the provision’s intent and explain once and for all how Bayh-Dole’s march-in right can and cannot be used.

December 16, 2020

Lessons Learned From Global Life Sciences Ecosystems in the COVID-19 Pandemic

ITIF hosted a discussion on this critical issue. The event featured a keynote address by Simon Tripp of TEConomy Partners, author of the new report “Response and Resilience: Lessons Learned from Global Life Sciences Ecosystems in the COVID-19 Pandemic,” followed by an expert panel of respondents.

More Events

Staff

StephenStephen Ezell

Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation

Advisors

BillBill Andresen

Associate Vice President for Federal Affairs, University of Pennsylvania

DavidDavid Beier

Managing Director, Bay City Capital

AndreiAndrei Iancu

Partner, Irell & Manella, LLP

Frank R.Frank R. Lichtenberg

Cain Brothers & Company Professor of Healthcare, Columbia University Graduate School of Business

CatherineCatherine Marinac

Assistant Professor of Medicine, Harvard Medical School

GaryGary Puckrein

Founding President and CEO, National Minority Quality Forum

More From the Center

June 24, 2022|Publications

Postmortem on a Pyrrhic Victory for IP Foes at the WTO

The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.

June 17, 2022|Publications

No, America’s Drug Prices Aren’t Climbing Radically Out of Control

The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.

June 6, 2022|Publications

About ITIF’s Center for Life Sciences Innovation

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.

March 15, 2022|Publications

‘March-In’ Advocates Continue the Assault on Life-Sciences Innovation System

America’s world-leading life-sciences innovation system is a product of myriad policies, but one that is all too often overlooked is the Bayh-Dole Act, which gives IP rights to universities that produce innovation with federally funded R&D.

November 22, 2021|Publications

Drug Price Controls Are Bad Policy. Congress Should Instead Double Down on Innovation to Boost Productivity in Biopharma R&D

Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.

April 29, 2021|Publications

Ten Ways IP Has Enabled Innovations That Have Helped Sustain the World Through the Pandemic

From vaccines and therapeutics to delivery robots, intellectual property has played an indispensable role in facilitating development of a range of inventive products that have helped address health care, work, and social challenges brought on by the pandemic.

April 19, 2021|Publications

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Blood-based multi-cancer early detection (MCED) technologies hold the promise to revolutionize America’s cancer-screening paradigm, dramatically expanding the range of detectable cancers and identifying them at earlier stages when cancers are more treatable. Policymakers should provide a supportive regulatory and coverage environment.

See All

Back to Top